FiBAN Case Hearing: BiopSense (Online)
BiopSense is building the missing pre-analytics layer for liquid biopsy: a disposable, fully automated cfDNA isolation cartridge that standardizes extraction, stabilization, quantification and QC at the point of collection. The solution targets a estimated €100M SOM by 2030, addressing a critical bottleneck where 68% of sample errors occur before analysis.
Delivers >30% higher cfDNA yield, effectively eliminates bad samples, requires just 1 minute of hands-on time, and removes cold-chain and transport restrictions.
Cuts sample-related costs by approximately 50%, with a recurring razor-and-blade business model targeting 70-85% gross margins on disposable cartridges.
Validated through 70+ lab and distributor leads, with pilots agreed across cancer care, NGS diagnostics, veterinary diagnostics, biotech and private healthcare.
Backed by a multidisciplinary team spanning clinical oncology, DNA/RNA technology, chemistry, electronics, medical engineering, R&D and management.
Currently raising a €1.2M bridge round to complete product industrialization, customer validation, certification and commercial launch.
Targeting a €5M growth round in 2027 to scale manufacturing, accelerate commercial growth and expand internationally.
Vision: become the infrastructure layer that makes liquid biopsy more sensitive, reliable and globally scalable.
Join us online to hear from the founder, lead investors ask your questions and get the answers. No strings attached. If you find your next investment case here, great! If not, on to the next one!
Agenda:
- Intro by founders (5-10min)
- Latest progress from company (5-10min)
- Lead/committed investor comments (3min)
- Q&A (20-30min)
This is a FiBAN investor event, outside participants allowed with strong referrals.